Abstract:Objective To explore the susceptibility of Aspergillus biofilms to common antifungal drugs and molecular mechanisms of antifungal drug resistance of Aspergillus biofilms. Methods The susceptibility of planktonic spores of 22 clinical isolates of Aspergillus spp. to amphotericin B, caspofungin and voriconazole was evaluated by a standard broth microdilution method. Meanwhile, in vitro model of Aspergillus spp. biofilm was established for the 22 isolates, then the susceptibility of Aspergillus spp. biofilm to amphotericin B, caspofungin and voriconazole was evaluated by a method for antifungal susceptibility testing combined with colonmetric XTT-reduction assay. In addition, real-time reverse transcription (RT)-PCR was performed to determine the relative expressions of drug efflux pump genes and azole target enzyme genes during the formation of Aspergillus spp. biofilms. Results In terms of planktonic spores of Aspergillus spp., the- minimal inhibitory concentration (MIC) range was 0.5 to 2 mg/L for amphotericin B, 0.5 to 1 mg/L for voriconazole, and the minimal effective concentration (MEC) range was 0.125 to 0.25 mg/L for caspofungin. As far as Aspergillus spp.biofilms was concerned, the sessile minimum concentration required to inhibit the growth of 50% organisms (SMIC50) and 80% organisms (SMIC80) ranged from 2 to > 32 mg/L and from 8 to > 32 mg/L, respectively, for amphotericin B, from 32 to > 256 mg/L and from 256 to >256 mg/L respectively for caspofungin, from 4 to >256 mg/L and from 32 to > 256 mg/L, respectively for voriconazole. During the formation of Aspergillus spp.biofilms, no change was observed for the expression of any of the 7 tested drug efflux pump genes or azole target enzyme genes at 4 hours, while a significant increase was noted in the expression of AfuMDRl, CYP51B and CYP51A genes at 8 hours, as well as in the expression of AfuMDRl, AfuMDR2, AfuMDR4, CYP51A,CYP51B at 12, 16 and 24 hours. Of these genes, CYP51A showed the strongest increase in expression at the above 4 time points. The expression of AfuMDR3 and atrF experienced no significant change during the formation of Aspergillus spp. biofilms. Conclusions Compared to planktonic spores, Aspergillus spp. biofilms exhibit a decreased susceptibility to amphotericin B, caspofungin and voriconazole. After the formation of biofilms, the expression of drug efflux pump genes and azole target enzyme genes is elevated in Aspergillus spp.

In Vitro Activity of 23 Antifungal Drugs against 54 Clinical and Environmental Aspergillus oryzae isolates

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

Antifungal Activity of Statins Against Aspergillus Species.

In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

Mutation in Cyp51a and High Expression of Efflux Pump Gene of Aspergillus Fumigatus Induced by Propiconazole in Liquid Medium and Soil.

Genotyping and Antifungal Susceptibility Testing of Aspergillus flavus Isolated from Clinical Specimens

In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against Aspergillus fumigatus with and without CYP51 Alterations

In vitro activities of nine antifungal agents against rare pathogenic fungi.

Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals

Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran

In Vitro Antifungal Activity of Selected Essential Oils against Drug-Resistant Clinical Aspergillus spp. Strains

In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

In Vitro Combination of Terbinafine with Ketoconazole Against Aspergillus Species with Terbinafine High MIC Values Isolated From Otomycosis

Antifungal susceptibility testing of clinical isolates of itraconazole-resistant Aspergillus fumigatus to four antifungal drugs

Antifungal susceptibility test for pathogenic Fusarium spp in vitro

Susceptibility testing of Aspergillus biofilms against common antifungal drugs and a preliminary study on molecular mechanisms of antifungal drug resistance in Aspergillus biofilms

In vitro antifungal susceptibility profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group (ECIFIG)

In Vitro Activity of Ibuprofen Against Clinical Isolates of Aspergillus

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023

In Vitro Activities of Nine Antifungal Drugs and Their Combinations against Phialophora verrucosa